CLEVELAND, Jan. 22, 2019 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today the five-year anniversary of patient
treatments with MRIdian MRI-guided radiation therapy at Siteman
Cancer Center at Barnes-Jewish Hospital and Washington
University School of Medicine in St. Louis, Missouri.
As one of the world's leading cancer centers, Siteman is known
for pioneering the advancement and adoption of innovative
technologies with a focus on improving patient care and
outcomes.
"We congratulate the Siteman team on reaching this milestone and
commend them for their thought-leadership, innovation and
commitment to cutting-edge cancer care," said Scott Drake, President and Chief Executive
Officer of ViewRay. "As the first center to treat with MRIdian,
they helped pave the way for the broader adoption of MRI-guided
radiation therapy we're seeing today."
In January 2014, Siteman Cancer
Center became the first center to treat patients using the world's
first MRI-guided radiation therapy system – MRIdian by ViewRay. The
center also was the first to perform adaptive radiation therapy
under MRI-guidance, a practice that is now a routine part of
treatment at Siteman. This adaptive therapy allows clinicians to
adapt to changes and movement in the patient's anatomy in real-time
while the patient is being treated, bringing greater precision to
radiation delivery.
"The availability of a system capable of combining MRI and
radiation therapy was an advance that the radiation oncology
community had eagerly awaited, so we were thrilled to be the first
to treat patients with the technology in 2014," said Jeff Michalski, M.D., Carlos A. Perez
Distinguished Professor, Vice Chair and Director of Clinical
Programs in Radiation Oncology at Siteman Cancer Center and
Washington University School of
Medicine. "The ability to track anatomical and tumor changes
in real-time enables us to target tumors, while more precisely
sparing healthy tissue. This technology greatly adds to the arsenal
of cancer treatments we offer to patients."
In November 2017, Siteman acquired
its second MRIdian System – the MRIdian Linac – following
FDA-clearance of this next generation technology from ViewRay,
which features MRI-guidance and linear accelerator delivery.
"The addition of both MRIdian systems has changed the way we
deliver radiation. We can capture soft tissue images of the
patient's body simultaneously during treatment. We can perform
real-time contouring, optimization and quality assurance while the
patient is being treated. We can treat tumors in close proximity to
organs-at-risk, even using high-dose radiation," said Dennis E. Hallahan, M.D., FASTRO, Elizabeth H.
and James S. McDonnell III Distinguished Professor of Medicine
Chair, Department of Radiation Oncology at Washington University.
Over the past five years, the Siteman team has been active in
sharing its clinical experience to advance the practice of
MRI-guided radiation therapy. Clinicians from Siteman have
presented more than 90 papers and posters at major medical meetings
and published more than 40 studies in peer-reviewed medical
journals, highlighting their experience with MRI-guided radiation
therapy. The department is currently involved in four clinical
trials to explore MRI-guided radiation therapy for pancreas,
breast, lung, and spine. To date, the MRIdian system at Siteman
Cancer Center has been used to treat more than 890 patients, 2,200
adaptive therapy sessions and more than 15 different
indications.
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets
the MRIdian® radiation therapy system. MRIdian is built upon a
proprietary high-definition MR imaging system designed from the
ground up to address the unique challenges and clinical workflow
for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purpose
built to address specific challenges, including beam distortion,
skin toxicity, and other concerns that potentially may arise when
high magnetic fields interact with radiation beams. ViewRay and
MRIdian are registered trademarks of ViewRay, Inc.
Intended Use: The MRIdian Linac System, with magnetic
resonance imaging capabilities, is intended to provide stereotactic
radiosurgery and precision radiotherapy for lesions, tumors, and
conditions anywhere in the body where radiation treatment is
indicated.
Forward Looking Statements: This press release
contains forward-looking statements. Statements in this press
release that are not purely historical are forward-looking
statements. These statements are subject to risks and uncertainties
that could cause future results to differ materially from those
referenced. Forward looking statements include, but are not limited
to references to the recent study results, clinical trial results,
related clinical experience and patient outcomes. Given these
uncertainties, the reader is advised not to place any undue
reliance on any forward-looking statements. Additional risk factors
include, among others, the ability to raise the additional funding
needed to continue to pursue ViewRay's business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, competition in the
industry in which ViewRay operates, government and regulatory
uncertainty, including but not limited to obtaining authorizations
to market and new tariffs and trade restrictions, and overall
market conditions. These forward-looking statements are made as of
the date of this press release, and ViewRay assumes no obligation
to update the forward-looking statements, or to update the reasons
why actual results differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents ViewRay files with the SEC available at
www.sec.gov.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/worlds-first-mridian-center-celebrates-five-years-of-mri-guided-radiation-treatments-300781659.html
SOURCE ViewRay, Inc.